Subscribe to RSS
DOI: 10.1055/s-0034-1366670
Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes (Teil 1)
Langfassung, Version 3, August 2013, AWMF-Registernr.: nvl-001gNational Disease Management Guideline Therapy of Type 2 Diabetes (Part 1)Long Version, Version 3, August 2013, AWMF register no.: nvl-001gPublication History
Publication Date:
24 July 2014 (online)

Inhaltsverzeichnis |
|
I. |
Einführung |
II. |
Zielsetzung, Adressaten und Anwendungsbereich |
Zielsetzung und Fragestellung |
|
Adressaten und Anwendungsbereich |
|
III. |
Quellen/Auswahl und Bewertung der NVL-Empfehlungen |
Auswahl der Quell-Leitlinien |
|
Adaptation der Quell-Leitlinien |
|
Evidenz- und Empfehlungsgrade |
|
IV. |
Verwendete Abkürzungen |
H. |
Hintergrund und Evidenz |
H 1. |
Definition, Pathophysiologie und Klassifikation des Typ-2-Diabetes |
H 1.1 |
Definition |
H 1.2 |
Vorbemerkungen zur Pathophysiologie |
H 1.3 |
Epidemiologie des Diabetes mellitus |
H 1.4 |
Ätiologische Klassifizierung des Diabetes mellitus |
H 1.5 |
Zur Problematik der Definition des Typ-2-Diabetes |
H 2. |
Therapieziele |
H 2.1 |
Definition der Begriffe Zielwerte, Zielkorridore und Therapieziele |
H 2.2 |
Allgemeine Therapieziele |
H 2.3 |
Spezifische Therapieziele |
H 2.3.1 |
Plasmaglukose versus HbA1c zur Kontrolle des Stoffwechsels bei Menschen mit Diabetes |
H 2.3.2 |
Orientierungsgrößen der Therapieziele: HbA1c |
H 2.3.3 |
Orientierungsgrößen der Therapieziele: Blutdruck, Lipide und Körpergewicht |
H 2.3.4 |
Zusammenfassung der Orientierungsgrößen zu Plasmaglukose, HbA1c, Lipiden, Blutdruck und Körpergewicht |
H 3. |
Diagnostik |
H 3.1. |
Diagnostik einer Glukosestoffwechselstörung |
H 3.1.1 |
Algorithmus zur Diagnose eines Typ-2-Diabetes |
H 3.2 |
Ätiologische Klassifizierung |
H 3.3 |
Differenzialdiagnose |
H 3.4 |
Anamnese und klinische Untersuchungen zur Verlaufskontrolle |
H 3.5 |
Diagnostik von Folge- und Begleiterkrankungen bei Typ-2-Diabetes |
H 3.5.1 |
Abschätzung des kardiovaskulären Risikos |
H 3.5.2 |
Abschätzung des Diabetesrisikos |
H 3.5.3 |
Untersuchungen auf weitere Folge- und Begleiterkrankungen |
H 4. |
Therapieindikationen und allgemeine Therapiealgorithmen |
H 5. |
Basistherapie |
H 5.1 |
Schulung |
H 5.1.1 |
Plasmaglukoseselbstmessung (SMBG) |
H 5.2 |
Ernährungstherapie und -beratung (Sekundärprävention) |
H 5.2.1 |
Ernährungstherapie |
H 5.2.2 |
Ernährungsberatung |
H 5.3 |
Körperliche Aktivität und Bewegung |
H 5.3.1 |
Ziele |
H 5.3.2 |
Formen körperlicher Aktivität und Bewegung |
H 5.4 |
Tabakentwöhnung |
-
Bundesärztekammer (Arbeitsgemeinschaft der Deutschen Ärztekammern) (BÄK)
http://www.baek.de
-
Kassenärztliche Bundesvereinigung (KBV)
http://www.kbv.de
-
Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)
http://www.awmf.org
sowie
-
Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ)
http://www.akdae.de
-
Deutsche Diabetes Gesellschaft (DDG)
http://www.deutsche-diabetes-gesellschaft.de
-
Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin (DEGAM)
http://www.degam.de
-
Deutsche Gesellschaft für Innere Medizin (DGIM) (vertreten durch die DDG)
http://www.dgim.de
-
Verband der Diabetesberatungs- und Schulungsberufe Deutschland (VDBD)
http://www.vdbd.de
Die Patientenbeteiligung wird durch die Kooperation mit dem Patientenforum gewährleistet.
Dieser Beitrag ist ein Nachdruck der NVL, deren Copyright das ÄZQ innehat. Ergänzungen und Modifikationen der Leitlinie sind über die Webseite http://www.diabetes.versorgungsleitlinien.de zugänglich.
1 Die genannten Autoren nahmen als offizielle Vertreter der jeweiligen Organisationen am Entstehungsprozess teil. Alle genannten Autoren sind Erstautoren; die Nennung erfolgte in alphabetischer Reihenfolge.
6 Qualitätssicherung: Unter „Qualitätssicherung“ sind Aktivitäten zu verstehen, die bei Kunden und Partnern im Gesundheitswesen Vertrauen schaffen, dass eine Organisation alle festgelegten, üblicherweise vorausgesetzten und verpflichtenden Erfordernisse und Erwartungen erfüllt – sprich eine exzellente Qualität erreicht. Qualitätssicherung kann in Form von Qualitätsnachweisen (z. B. Qualitätsberichte, Zertifizierungen, Qualitätspreise) erfolgen [604].
7 Qualitätsmanagement: Unter „Qualitätsmanagement“ versteht man aufeinander abgestimmte Tätigkeiten zum Leiten einer Institution (z. B. einer Arztpraxis) mit dem Ziel die Qualität der angebotenen Dienstleistungen zu sichern und letztendlich bei Bedarf zu verbessern [604]. Potenzielle Fehlerquellen oder Lücken in der Versorgung sollen identifiziert und beseitigt werden [604].
-
Literatur
- 1 Berger M, Grüsser M, Jörgens V et al. Behandlungs- und Schulungsprogramm für Typ-2-Diabetiker, die Insulin spritzen. Köln: Dt. Ärzte-Verl; 1989
- 2 Berger M, Grüsser M, Jörgens V et al. Behandlungs- und Schulungsprogramm für Typ-2-Diabetiker, die nicht Insulin spritzen. Köln: Dt. Ärzte-Verl; 1987
- 3 Anlauf-Wilhelm B, Fisch R, Gralki A et al. Den Füssen zu liebe (BARFUSS) – Strukturiertes Behandlungs- und Schulungsprogramm für Menschen mit Diabetes und einem diabetischen Fußsyndrom. 1999
- 4 Kulzer B, Hermanns N, Kubiak T et al. HyPOS – Unterzuckerungen besser wahrnehmen, vermeiden und bewältigen. Ein strukturiertes Schulungs- und Behandlungsprogramm für insulinpflichtige Diabetiker mit Hypoglykämieproblemen. Mainz: Kirchheim; 2006
- 5 Berger M, Grüsser M, Jörgens V. Behandlungs- und Schulungsprogramm für Typ-2-Diabetiker, die Normalinsulin spritzen. Köln: Dt. Ärzte-Verl; 1987
- 6 Kulzer B, Hermanns N, Maier B et al. MEDIAS 2 – mehr Diabetes Selbstmanagement für Typ 2. Ein Schulungs- und Behandlungsprogramm für Menschen mit nicht-insulinpflichtigem Typ-2-Diabetes. Mainz: Kirchheim; 2001
- 7 Brinkmeier U, Tewes A, Tegtbur U. Diabetes & Verhalten. Schulungsprogramm für Menschen mit Typ-2-Diabetes, die Insulin spritzen. Mainz: Kirchheim; 2009
- 8 Kulzer B, Hermanns N, Maier B et al. MEDIAS 2 – mehr Diabetes Selbstmanagement für Typ 2. Ein Schulungs- und Behandlungsprogramm für Menschen Typ-2-Diabetes und einer intensivierten Insulintherapie (ICT). Mainz: Kirchheim; 2011
- 9 Ärztliche Zentralstelle Qualitätssicherung (ÄZQ). Leitlinien-Clearingbericht "Diabetes mellitus Typ 2". München: Zuckschwerdt; 2001 (äzq Schriftenreihe; 8). Available from: http://www.leitlinien.de/leitlinienmethodik/clearingverfahren/aezq/clearingverfahren_99-05/clearingberichte/leitlinien-clearingverfahren-diabetes-mellitus%20
- 10 Colberg SR, Albright AL, Blissmer BJ et al. Exercise and type 2 diabetes: American College of Sports Medicine and the American Diabetes Association: joint position statement. Exercise and type 2 diabetes. Med Sci Sports Exerc 2010; 42 (12) 2282-2303 http://www.ncbi.nlm.nih.gov/pubmed/21084931
- 11 Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35 (06) 1364-1379 DOI: 10.2337/dc12-0413. http://www.ncbi.nlm.nih.gov/pubmed/22517736
- 12 Bantle JP, Wylie-Rosett J, Albright AL et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 2008; 31 (Suppl. 01) S61-S78 http://www.ncbi.nlm.nih.gov/pubmed/18165339
- 13 American Diabetes Association (ADA). Standards of medical care in diabetes – 2009. Diabetes Care 2009; 32 (Suppl. 01) S13-S61 http://www.ncbi.nlm.nih.gov/pubmed/19118286.
- 14 American Diabetes Associatio (ADA). Standards of medical care in diabetes – 2012. Diabetes Care 2012; 35 (Suppl. 01) S11-S63 DOI: 10.2337/dc12-s011. http://www.ncbi.nlm.nih.gov/pubmed/22187469
- 15 Franz MJ, Powers MA, Leontos C et al. The evidence for medical nutrition therapy for type 1 and type 2 diabetes in adults. J Am Diet Assoc 2010; 110 (12) 1852-1889 http://www.ncbi.nlm.nih.gov/pubmed/21111095
- 16 Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ). Empfehlungen zur antihyperglykämischen Therapie des Diabetes mellitus Typ 2. 2. Aufl.. 2009 [cited: 2013 Jul 02]. Available from: http://www.akdae.de/Arzneimitteltherapie/TE/A-Z/PDF/Diabetes2.pdf
- 17 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Typ-2-Diabetes-Präventions- und Behandlungsstrategien für Fußkomplikationen. 2006 [cited: 2013 Jul 01]. Available from: http://www.versorgungsleitlinien.de/themen/diabetes2/dm2_fuss/index_html
- 18 Bundesärztekammer (BÄK), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Kassenärztliche Bundesvereinigung (KBV). Nationale VersorgungsLeitlinie Typ-2-Diabetes-Prävention und Therapie von Netzhautkomplikationen. 2006 [cited: 2013 Apr 08]. Available from: http://www.versorgungsleitlinien.de/themen/diabetes2/dm2_netzhaut/index_html
- 19 Bundesärztekammer (BÄK), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Kassenärztliche Bundesvereinigung (KBV). Nationale VersorgungsLeitlinie Nierenerkrankungen bei Diabetes im Erwachsenenalter. Langfassung. 2010 [cited: 2013 Mae 05]. Available from: http://www.versorgungsleitlinien.de/themen/diabetes2/dm2_nephro
- 20 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische KHK. Langfassung. Köln: Dt. Ärzte-Verl; 2007 Available from: http://www.khk.versorgungsleitlinien.de
- 21 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Neuropathie bei Diabetes im Erwachsenenalter. 2011 [cited: 2013 Jul 01]. Available from: http://www.versorgungsleitlinien.de/themen/diabetes2/dm2_neuro
- 22 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Diabetes. Strukturierte Schulungsprogramme – Langfassung. Version 1.0. 2012 [cited: 2013 Jan 02]. Available from: DOI: 10.6101/AZQ/000083 http://www.versorgungsleitlinien.de/themen/diabetes2/dm2_schulung
- 23 Scherbaum WA, Haak T, Halle M et al. Körperliche Aktivität und Diabetes mellitus. Evidenzbasierte Leitlinie der Deutschen Diabetes-Gesellschaft. 2008 [cited: 2013 Jul 04]. Available from: http://www.awmf.org/uploads/tx_szleitlinien/057-022_S3_Koerperliche_Aktivitaet_und_Diabetes_mellitus_10-2008_10-2013.pdf
- 24 Matthaei S, Bierwirth R, Fritsche A et al. Medikamentöse antihyperglykämische Therapie des Diabetes mellitus Typ 2. Update der Evidenzbasierten Leitlinie der Deutschen Diabetes-Gesellschaft. Diabetologie 2009; 4: 32-64 http://www.deutsche-diabetes-gesellschaft.de/fileadmin/Redakteur/Leitlinien/Evidenzbasierte_Leitlinien/EBL_Dm_Typ2_Update_2008.pdf
- 25 Zeyfang A, Bahrmann A, Wernecke J. Diabetes mellitus im Alter. Diabetologie 2012; 7 (Suppl. 02) S163-S169 DOI: 10.1055/s-0032-1325571.
- 26 Kemmer FW, Halle M, Stumvoll M et al. Diabetes, Sport und Bewegung. Praxisleitlinie der Deutschen Diabetes-Gesellschaft. Diabet Stoffw 2009; 4 (Suppl. 02) S113-S200 https://www.thieme-connect.com/ejournals/abstract/10.1055/s-0029-1224571
- 27 Kulzer B, Albus C, Herpertz S et al. Psychosoziales und Diabetes mellitus. Diabet Stoffw 2012; 7 S02: S136-S142 DOI: 10.1055/s-0032-1325580. https://www.thieme-connect.com/ejournals/abstract/10.1055/s-0032-1325580
- 28 Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN), Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression. 2009 [cited: 2013 Jul 01]. Available from: http://www.versorgungsleitlinien.de/themen/depression
- 29 Leitliniengruppe Hessen. Diabetes mellitus Typ 2. Therapie des Diabetes mellitus Typ 2. Hausärztliche Leitlinie. 2007 [cited: 2013 Jul 02]. Available from: http://www.pmvforschungsgruppe.de/pdf/03_publikationen/diabetes_ll.pdf
- 30 National Institute for Health and Clinical Excellence (NICE). Type 2 diabetes: the management of type 2 diabetes (update). 2008 [cited: 2013 Jul 01]. Available from: http://guidance.nice.org.uk/CG66
- 31 Scottish Intercollegiate Guidelines Network (SIGN). Management of diabetes. A national clinical guideline. Edinburgh: SIGN; 2010 (SIGN Publications; 116). Available from: http://www.sign.ac.uk/pdf/sign116.pdf
- 32 Toeller M. Ernährungsempfehlungen bei Diabetes und deren Implementierung. Update anhand ausgewählter Publikationen. Diabetologe 2009; 5 (06) 442-452 http://link.springer.com/article/10.1007/s11428-009-0405-1.
- 33 Toeller M. Evidenz-basierte Ernährungsempfehlungen zur Behandlung und Prävention des Diabetes mellitus. Autorisierte deutsche Version nach: Diabetes and Nutrition Study Group (DNSG). (Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus. Nutr Metab Cardiovasc Dis 14(2004) 373–394 Diabet Stoffw 2005; 14: 75-94 http://www.deutsche-diabetes-gesellschaft.de/fileadmin/Redakteur/Leitlinien/Evidenzbasierte_Leitlinien/EBL_Ernaehrung_2005.pdf
- 34 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationales Programm für VersorgungsLeitlinien. Methoden-Report. 4 Aufl. 2010 [cited: 2013 Mae 05]. Available from: DOI: 10.6101/AZQ/000061 http://www.versorgungsleitlinien.de/methodik/pdf/nvl_methode_4.aufl.pdf
- 35 Europarat, Verbindung der Schweizer Ärztinnen und Ärzte, Ärztliche Zentralstelle Qualitätssicherung, Ludwig Boltzmann Institut für Krankenhausorganisation. Entwicklung einer Methodik für die Ausarbeitung von Leitlinien für optimale medizinische Praxis. Empfehlung Rec (2001)13 des Europarates am 10. Oktober 2001 und Erläuterndes Memorandum. Deutschsprachige Ausgabe. Z Arztl Fortbild Qualitatssich 2002; 96 (Suppl. 03) 3-60 http://www.leitlinien.de/mdb/edocs/pdf/literatur/europaratmethdt.pdf
- 36 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV). Beurteilungskriterien für Leitlinien in der medizinischen Versorgung – Beschlüsse der Vorstände der Bundesärztekammer und Kassenärztlicher Bundesvereinigung, Juni 1997. Dtsch Arztebl 1997; 94 (33) A 2154-A 2155 http://www.aerzteblatt.de/pdf/94/33/a2154-5.pdf
- 37 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Erarbeitung von Leitlinien für Diagnostik und Therapie. Methodische Empfehlungen ("Leitlinie für Leitlinien", Stand Dezember 2004). 2004 [cited: 2012 Mai 31]. Available from: http://www.awmf.org/fileadmin/user_upload/Leitlinien/Werkzeuge/Publikationen/methoden.pdf
- 38 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV). Das Leitlinien-Clearingverfahren von Bundesärztekammer und Kassenärztlicher Bundesvereinigung in Zusammenarbeit mit der Deutschen Krankenhausgesellschaft und den Spitzenverbänden der Gesetzlichen Krankenversicherungen, Ziele und Arbeitsplan. Dtsch Arztebl 1999; 96 (33) A2105-A2106 http://www.aerzteblatt.de/v4/archiv/pdf.asp?id=18624
- 39 Ärztliches Zentrum für Qualität in der Medizin (ÄZQ), Ärztliche Zentralstelle Qualitätssicherung (ÄZQ). Leitlinien-Clearingberichte, 1999–2005. 2005 [cited: 2013 Mae 05]. Available from: http://www.leitlinien.de/leitlinienmethodik/clearingverfahren/aezq/clearingverfahren_99-05
- 40 Ärztliches Zentrum für Qualität in der Medizin (ÄZQ), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Deutsches Instrument zur methodischen Leitlinien-Bewertung (DELBI). Fassung 2005/2006. Z Arztl Fortbild Qualitatssich 2005; 99 (08) 468-519
- 41 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Das AWMF-Regelwerk Leitlinien. 2012 Available from: http://www.awmf.org/leitlinien/awmf-regelwerk.html
- 42 Ollenschläger G, Marshall C, Qureshi S et al. Improving the quality of health care: using international collaboration to inform guideline programmes by founding the Guidelines International Network (G-I-N). Qual Saf Health Care 2004; 13 (06) 455-460 http://www.ncbi.nlm.nih.gov/pubmed/15576708
- 43 New Zealand Guidelines Group (NZGG). Handbook for the preparation of explicit evidence-based clinical practice guidelines. Wellington: NZGG; 2001
- 44 Leitliniengruppe Hessen. Leitlinienreport-Allgemeiner Leitlinienreport. Version 3.00, Stand Januar 2009. 2009 [cited: 2012 Mai 31]. Available from: http://www.pmvforschungsgruppe.de/pdf/03_publikationen/allgemein_report.pdf
- 45 Ollenschläger G, Thomeczek C, Thalau F et al. Medizinische Leitlinien in Deutschland, 1994 bis 2004. Von der Leitlinienmethodik zur Leitlinienimplementierung. Z Arztl Fortbild Qualitatssich 2005; 99 (01) 7-13 http://www.ncbi.nlm.nih.gov/pubmed/15804124
- 46 Schneider M, Lelgemann M. Methodenreport zur Entwicklung der Leitlinie „Management der frühen rheumatoiden Arthritis“. Anlage 1 zu „Management der frühen rheumatoiden Arthritis. Interdisziplinäre Leitlinie“. Berlin: DGRh; 2004
- 47 Fervers B, Remy-Stockinger M, Graham ID et al. Guideline adaptation: an appealing alternative to de novo guideline development. Ann Intern Med 2008; 148 (07) 563-564 http://www.ncbi.nlm.nih.gov/pubmed/18378955
- 48 Fervers B, Burgers JS, Haugh MC et al. Adaptation of clinical guidelines: literature review and proposition for a framework and procedure. Int J Qual Health Care 2006; 18 (03) 167-176 http://www.ncbi.nlm.nih.gov/pubmed/16766601
- 49 Atkins D, Best D, Briss PA et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328 (7454) 1490-1497 http://www.ncbi.nlm.nih.gov/pubmed/15205295
- 50 Guyatt GH, Oxman AD, Vist GE et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336 (7650) 924-926 http://www.ncbi.nlm.nih.gov/pubmed/18436948
- 51 Dunham RB. Nominal Group Technique: A Users' guide. Madison: Wisconsin School of Business; 1998
- 52 Murphy MK, Black NA, Lamping DL et al. Consensus development methods, and their use in clinical guideline development. Health Technol Assess 1998; 2 (03) i-88 http://www.ncbi.nlm.nih.gov/pubmed/9561895
- 53 Stinner B, Bauhofer A, Sitter H et al. Nominaler Gruppenprozess als Konsensusinstrument zur Einschränkung der Therapieheterogenität in einer komplexen "outcome"-Studie. Intensivmed Notfallmed 2000; 37 (Suppl. 02) 30
- 54 Bundesärztekammer (BÄK), Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ), Deutsche Diabetes Gesellschaft (DDG), Fachkommission Diabetes Sachsen (FDS), Deutsche Gesellschaft für Innere Medizin (DGIM), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale Versorgungs-Leitlinie Diabetes mellitus Typ 2. Köln: BÄK; 2002
- 55 Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355 (23) 2427-2443 http://www.ncbi.nlm.nih.gov/pubmed/17145742
- 56 U. K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U. K. Prospective Diabetes Study Group. Diabetes 1995; 44 (11) 1249-1258 http://www.ncbi.nlm.nih.gov/pubmed/7589820
- 57 Holman RR. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract 1998; 40 Suppl: S21-S25 http://www.ncbi.nlm.nih.gov/pubmed/9740498
- 58 Zimmet P, Alberti KG MM, Serrano RiosM. A new international diabetes federation worldwide definition of the metabolic syndrome: the rationale and the results. Rev Esp Cardiol 2005; 58 (12) 1371-1376 http://www.ncbi.nlm.nih.gov/pubmed/16371194
- 59 Schulze MB, Hoffmann K, Boeing H et al. An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes. Diabetes Care 2007; 30 (03) 510-515 http://www.ncbi.nlm.nih.gov/pubmed/17327313
- 60 Kurth BM. Erste Ergebnisse aus der „Studie zur Gesundheit Erwachsener in Deutschland" (DEGS). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2012; 55 (08) 980-990
- 61 Rathmann W, Scheidt-Nave C, Roden M et al. Type 2 diabetes: prevalence and relevance of genetic and acquired factors for its prediction. Dtsch Arztebl Int 2013; 110 (19) 331-337 DOI: 10.3238/arztebl.2013.0331. http://www.ncbi.nlm.nih.gov/pubmed/23762204
- 62 Heidemann C, Du Y, Scheidt-Nave C. , Robert Koch Institut (RKI). Diabetes mellitus in Deutschland. 2011 [cited: 2013 Jul 04]. Available from: http://www.rki.de/DE/Content/Gesundheitsmonitoring/Gesundheitsberichterstattung/GBEDownloadsK/2011_3_diabetes.pdf?__blob=publicationFile
- 63 Nordrheinische Gemeinsame Einrichtung Disease-Management-Programme. Qualitätssicherungsbericht 2010. Disease-Management-Programme in Nordrhein. Brustkrebs, Diabetes mellitus Typ 1/Typ 2, Koronare Herzkrankheit, Asthma/COPD. Düsseldorf: Nordrheinische Gemeinsame Einrichtung DMP; 2011
- 64 Samann A, Tajiyeva O, Muller N et al. Prevalence of the diabetic foot syndrome at the primary care level in Germany: a cross-sectional study. Diabet Med 2008; 25 (05) 557-563 http://www.ncbi.nlm.nih.gov/pubmed/18346154
- 65 Blum M, Kloos C, Muller N et al. Prevalence of diabetic retinopathy. Check-up program of a public health insurance company in Germany 2002–2004. Ophthalmologe 2007; 104 (06) 499-504 http://www.ncbi.nlm.nih.gov/pubmed/17457588.
- 66 Nordrheinische Gemeinsame Einrichtung Disease-Management-Programme. Qualitätssicherungsbericht 2009. Disease-Management-Programme in Nordrhein. Brustkrebs, Diabetes mellitus Typ 1/Typ 2, Koronare Herzkrankheit, Asthma/COPD. Düsseldorf: Nordrheinische Gemeinsame Einrichtung DMP; 2010
- 67 Perna L, Thien-Seitz U, Ladwig KH et al. Socio-economic differences in life expectancy among persons with diabetes mellitus or myocardial infarction: results from the German MONICA/KORA study. BMC Public Health 2010; 10: 135 http://www.ncbi.nlm.nih.gov/pubmed/20233394.
- 68 Miksch A, Laux G, Ose D et al. Is there a survival benefit within a German primary care-based disease management program?. Am J Manag Care 2010; 16 (01) 49-54 http://www.ncbi.nlm.nih.gov/pubmed/20148605
- 69 American Diabetes Association (ADA). Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33 (Suppl. 01) S62-S69 http://www.ncbi.nlm.nih.gov/pubmed/20042775.
- 70 World Health Organization (WHO), International Diabetes Federation (IDF). Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Report of a WHO/IDF Consultation 2006 [cited: 2013 Jul 04]. Available from: http://www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf
- 71 American Diabetes Association (ADA). Diagnosis and classification of diabetes mellitus. Diabetes Care 2006; 29 (Suppl. 01) S43-S48 http://www.ncbi.nlm.nih.gov/pubmed/16373932
- 72 Hawa MI, Kolb H, Schloot N et al. Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7. Diabetes Care 2013; 36 (04) 908-913 DOI: 10.2337/dc12-0931. http://www.ncbi.nlm.nih.gov/pubmed/23248199
- 73 Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444 (7121) 840-846 http://www.ncbi.nlm.nih.gov/pubmed/17167471
- 74 American Diabetes Association (ADA). Standards of medical care in diabetes – 2006. Diabetes Care 2006; 29 (Suppl. 01) S4-S42 http://www.ncbi.nlm.nih.gov/pubmed/16373931
- 75 New Zealand Guidelines Group (NZGG). Management of Type 2 Diabetes. 2003 [cited: 2013 Jul 04]. Available from: http://www.nzgg.org.nz/guidelines/dsp_guideline_popup.cfm?guidelineCatID=30&guidelineID=36
- 76 American Diabetes Association (ADA). Standards of medical care in diabetes – 2010. Diabetes Care 2010; 33 (Suppl. 01) S11-S61 http://www.ncbi.nlm.nih.gov/pubmed/20042772
- 77 Benjamin EM, Schneider MS, Hinchey KT. Implementing practice guidelines for diabetes care using problem-based learning. A prospective controlled trial using firm systems. Diabetes Care 1999; 22 (10) 1672-1678 http://www.ncbi.nlm.nih.gov/pubmed/10526733
- 78 Olivarius NF, Beck-Nielsen H, Andreasen AH et al. Randomised controlled trial of structured personal care of type 2 diabetes mellitus. BMJ 2001; 323 (7319) 970-975 http://www.ncbi.nlm.nih.gov/pubmed/11679387
- 79 Greenfield S, Kaplan SH, Ware Jr JE et al. Patients' participation in medical care: effects on blood sugar control and quality of life in diabetes. J Gen Intern Med 1988; 3 (05) 448-457 http://www.ncbi.nlm.nih.gov/pubmed/3049968
- 80 Pill R, Stott NC, Rollnick SR et al. A randomized controlled trial of an intervention designed to improve the care given in general practice to Type II diabetic patients: patient outcomes and professional ability to change behaviour. Fam Pract 1998; 15 (03) 229-235 http://www.ncbi.nlm.nih.gov/pubmed/9694180
- 81 Janka HU, Balletshofer B, Becker A. Das metabolische Syndrom als potenter Risikofaktor für frühzeitigen Tod bei Typ 2 Diabetikern. Die Schwabinger Studie II – Untersuchungen nach 9 Jahren. Diabet Stoffw 1992; 1: 2-7
- 82 Laakso M, Kuusisto J. Epidemiological evidence for the association of hyperglycaemia and atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Ann Med 1996; 28 (05) 415-418 http://www.ncbi.nlm.nih.gov/pubmed/8949972
- 83 Uusitupa M, Siitonen O, Aro A et al. Prevalence of coronary heart disease, left ventricular failure and hypertension in middle-aged, newly diagnosed type 2 (non-insulin-dependent) diabetic subjects. Diabetologia 1985; 28 (01) 22-27 http://www.ncbi.nlm.nih.gov/pubmed/3979684
- 84 Bundesärztekammer (BÄK), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Kassenärztliche Bundesvereinigung (KBV). Nationale Versorgungs Leitlinie KHK. 2006 [cited: 2012 Mär 30]. Available from: http://www.versorgungsleitlinien.de/themen/khk
- 85 Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321 (7258) 405-412 http://www.ncbi.nlm.nih.gov/pubmed/10938048
- 86 de Vegt F, Dekker JM, Ruhe HG et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999; 42 (08) 926-931 http://www.ncbi.nlm.nih.gov/pubmed/10491751
- 87 Selvin E, Wattanakit K, Steffes MW et al. HbA1c and peripheral arterial disease in diabetes: the Atherosclerosis Risk in Communities study. Diabetes Care 2006; 29 (04) 877-882 http://www.ncbi.nlm.nih.gov/pubmed/16567831
- 88 Selvin E, Coresh J, Shahar E et al. Glycaemia (haemoglobin A1c) and incident ischaemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. Lancet Neurol 2005; 4 (12) 821-826 http://www.ncbi.nlm.nih.gov/pubmed/16297840
- 89 Selvin E, Coresh J, Golden SH et al. Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med 2005; 165 (16) 1910-1916 http://www.ncbi.nlm.nih.gov/pubmed/16157837
- 90 Khaw KT, Wareham N, Bingham S et al. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004; 141 (06) 413-420 http://www.ncbi.nlm.nih.gov/pubmed/15381514
- 91 Coutinho M, Gerstein HC, Wang Y et al. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22 (02) 233-40 http://www.ncbi.nlm.nih.gov/pubmed/10333939
- 92 Selvin E, Marinopoulos S, Berkenblit G et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141 (06) 421-431 http://www.ncbi.nlm.nih.gov/pubmed/15381515
- 93 American Acadamy of Family Physicians (AAFP). The benefits and risks of controlling blood glucose levels in patients with type 2 diabetes mellitus. 2005 [cited: 2013 Jul 04]. Available from: http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.173.3576&rep=rep1&type=pdf
- 94 Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358 (24) 2560-2572 http://www.ncbi.nlm.nih.gov/pubmed/18539916
- 95 Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28 (02) 103-117 http://www.ncbi.nlm.nih.gov/pubmed/7587918
- 96 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352 (9131) 837-853 http://www.ncbi.nlm.nih.gov/pubmed/9742976
- 97 Lasker RD. The diabetes control and complications trial. Implications for policy and practice. N Engl J Med 1993; 329 (14) 1035-1036 http://www.ncbi.nlm.nih.gov/pubmed/8366905
- 98 UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352 (9131) 854-865 http://www.ncbi.nlm.nih.gov/pubmed/9742977
- 99 Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358 (24) 2545-2559 http://www.ncbi.nlm.nih.gov/pubmed/18539917
- 100 The ORIGIN Trial Investigators. Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. N Engl J Med 2012; DOI: 10.1056/NEJMoa1203858. http://www.ncbi.nlm.nih.gov/pubmed/22686416
- 101 Ray KK, Seshasai SR, Wijesuriya S et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373 (9677) 1765-1772 http://www.ncbi.nlm.nih.gov/pubmed/19465231
- 102 Kelly TN, Bazzano LA, Fonseca VA et al. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009; 151 (06) 394-403 http://www.ncbi.nlm.nih.gov/pubmed/19620144
- 103 Richter B, Lerch C. Metabolische Kontrolle beim Typ 2 Diabetes mellitus – alles unter oder außer Kontrolle?. Z Allg Med 2010; 85 (01) 14-18
- 104 Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011; 343: d4169 http://www.ncbi.nlm.nih.gov/pubmed/21791495
- 105 Hemmingsen B, Lund SS, Gluud C et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 2011; 343: d6898 http://www.ncbi.nlm.nih.gov/pubmed/22115901
- 106 Hemmingsen B, Lund SS, Gluud C et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011; (06) CD008143 http://www.ncbi.nlm.nih.gov/pubmed/21678374
- 107 Turnbull FM, Abraira C, Anderson RJ et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52 (11) 2288-2298 http://www.ncbi.nlm.nih.gov/pubmed/19655124
- 108 ACCORD Study Group. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus (ACCORD). N Engl J Med 2010; http://www.ncbi.nlm.nih.gov/pubmed/20228404
- 109 Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008; 358 (24) 2630-2633 http://www.ncbi.nlm.nih.gov/pubmed/18539918
- 110 Gaede P, Vedel P, Larsen N et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348 (05) 383-393 http://www.ncbi.nlm.nih.gov/pubmed/12556541
- 111 Wilson PW, D'Agostino RB, Parise H et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112 (20) 3066-3072 http://www.ncbi.nlm.nih.gov/pubmed/16275870
- 112 Kahn R, Buse J, Ferrannini E et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28 (09) 2289-2304 http://www.ncbi.nlm.nih.gov/pubmed/16123508
- 113 Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006; 49 (08) 1711-1721 http://www.ncbi.nlm.nih.gov/pubmed/16802130
- 114 Qaseem A, Vijan S, Snow V et al. Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians. Ann Intern Med 2007; 147 (06) 417-22 http://www.ncbi.nlm.nih.gov/pubmed/17876024
- 115 Ryden L, Standl E, Bartnik M et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28 (01) 88-136 http://www.ncbi.nlm.nih.gov/pubmed/17220161
- 116 American Diabetes Association (ADA). Standards of medical care in diabetes – 2007. Diabetes Care 2007; 30 (Suppl. 01) S4-S41 http://www.ncbi.nlm.nih.gov/pubmed/17192377
- 117 Canadian Diabetes Association. Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2008; 32 (Suppl. 01) 1-201
- 118 Psaty BM, Prentice RL. Variation in event rates in trials of patients with type 2 diabetes. JAMA 2009; 302 (15) 1698-1700 http://www.ncbi.nlm.nih.gov/pubmed/19843906
- 119 Currie CJ, Peters JR, Tynan A et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010; 375 (9713) 481-489 http://www.ncbi.nlm.nih.gov/pubmed/20110121
- 120 Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360 (02) 129-139 http://www.ncbi.nlm.nih.gov/pubmed/19092145
- 121 Donahue RP, Abbott RD, Reed DM et al. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes 1987; 36 (06) 689-692 http://www.ncbi.nlm.nih.gov/pubmed/3569669
- 122 Landgraf R. Approaches to the management of postprandial hyperglycaemia. Exp Clin Endocrinol Diabetes 1999; 107 (Suppl. 04) S128-S132 http://www.ncbi.nlm.nih.gov/pubmed/10522837
- 123 Shaw JE, Hodge AM, de Courten M et al. Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 1999; 42 (09) 1050-1054 http://www.ncbi.nlm.nih.gov/pubmed/10447514
- 124 Gerstein HC. Glucose: a continuous risk factor for cardiovascular disease. Diabet Med 1997; 14 (Suppl. 03) S25-S31 http://www.ncbi.nlm.nih.gov/pubmed/9272610
- 125 Hanefeld M, Temelkova-Kurktschiev T. The postprandial state and the risk of atherosclerosis. Diabet Med 1997; 14 (Suppl. 03) S6-S11 http://www.ncbi.nlm.nih.gov/pubmed/9272607
- 126 Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979; 2 (02) 131-141 http://www.ncbi.nlm.nih.gov/pubmed/520116
- 127 Haller H. Postprandial glucose and vascular disease. Diabet Med 1997; 14 (Suppl. 03) S50-S56 http://www.ncbi.nlm.nih.gov/pubmed/9272614
- 128 Tominaga M, Eguchi H, Manaka H et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999; 22 (06) 920-924 http://www.ncbi.nlm.nih.gov/pubmed/10372242
- 129 Leiter LA, Ceriello A, Davidson JA et al. Postprandial glucose regulation: new data and new implications. Clin Ther 2005; 27 (Suppl B) S42-S56 http://www.ncbi.nlm.nih.gov/pubmed/16519037
- 130 Home P. Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes. Curr Med Res Opin 2005; 21 (07) 989-998 http://www.ncbi.nlm.nih.gov/pubmed/16004665
- 131 Gerich JE. Postprandial hyperglycemia and cardiovascular disease. Endocr Pract 2006; 12 (Suppl. 01) 47-51 http://www.ncbi.nlm.nih.gov/pubmed/16627380
- 132 Ceriello A. The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications. Diabet Med 1998; 15 (03) 188-193 http://www.ncbi.nlm.nih.gov/pubmed/9545118
- 133 Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat?. Diabetes 2005; 54 (01) 1-7 http://www.ncbi.nlm.nih.gov/pubmed/15616004
- 134 Raz I, Wilson PW, Strojek K et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009; 32 (03) 381-386 http://www.ncbi.nlm.nih.gov/pubmed/19246588
- 135 American Diabetes Association (ADA). Postprandial blood glucose. American Diabetes Association. Diabetes Care 2001; 24 (04) 775-778 http://www.ncbi.nlm.nih.gov/pubmed/11315848
- 136 Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ). Empfehlungen zur Therapie von Tabakabhängigkeit. Köln: AkdÄ; 2001 (Arzneiverordnung in der Praxis; 2001). Available from: http://www.akdae.de/Arzneimitteltherapie/TE/Archiv/Tabakabhaengigkeit.pdf
- 137 Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ). Empfehlungen zur Prophylaxe und Therapie der stabilen koronaren Herzkrankheit. Köln: AkdÄ; 2004 (Arzneiverordnung in der Praxis; 31). Available from: http://www.akdae.de/Arzneimitteltherapie/TE/A-Z/PDF/KHK.pdf#page=1&view=fitB
- 138 Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ). Empfehlungen zur Therapie der arteriellen Hypertonie. 2nd ed. Köln: AkdÄ; 2004 (Arzneiverordnung in der Praxis; 31). Available from: http://www.akdae.de/Arzneimitteltherapie/TE/Archiv/Hypertonie.pdf
- 139 Adler AI, Stratton IM, Neil HA et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321 (7258) 412-419 http://www.ncbi.nlm.nih.gov/pubmed/10938049
- 140 Turner RC, Millns H, Neil HA et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998; 316 (7134) 823-828 http://www.ncbi.nlm.nih.gov/pubmed/9549452
- 141 UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317 (7160) 703-713 http://www.ncbi.nlm.nih.gov/pubmed/9732337
- 142 Klein R, Klein BE, Moss SE et al. Is blood pressure a predictor of the incidence or progression of diabetic retinopathy?. Arch Intern Med 1989; 149 (11) 2427-2432 http://www.ncbi.nlm.nih.gov/pubmed/2684072
- 143 ACCORD Study Group. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. N Engl J Med 2010; 362 (17) 1575-1585 http://www.ncbi.nlm.nih.gov/pubmed/20228401
- 144 Biesenbach G, Grafinger P, Janko O et al. Influence of cigarette-smoking on the progression of clinical diabetic nephropathy in type 2 diabetic patients. Clin Nephrol 1997; 48 (03) 146-150 http://www.ncbi.nlm.nih.gov/pubmed/9342485
- 145 Chase HP, Garg SK, Marshall G et al. Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes. JAMA 1991; 265 (05) 614-617 http://www.ncbi.nlm.nih.gov/pubmed/1987411
- 146 Forsblom CM, Groop PH, Ekstrand A et al. Predictors of progression from normoalbuminuria to microalbuminuria in NIDDM. Diabetes Care 1998; 21 (11) 1932-1938 http://www.ncbi.nlm.nih.gov/pubmed/9802746
- 147 Muhlhauser I, Bender R, Bott U et al. Cigarette smoking and progression of retinopathy and nephropathy in type 1 diabetes. Diabet Med 1996; 13 (06) 536-543 http://www.ncbi.nlm.nih.gov/pubmed/8799657
- 148 Faronato PP, Maioli M, Tonolo G et al. Clustering of albumin excretion rate abnormalities in Caucasian patients with NIDDM. The Italian NIDDM Nephropathy Study Group. Diabetologia 1997; 40 (07) 816-823 http://www.ncbi.nlm.nih.gov/pubmed/9243103
- 149 Roglic G, Colhoun HM, Stevens LK et al. Parental history of hypertension and parental history of diabetes and microvascular complications in insulin-dependent diabetes mellitus: the EURODIAB IDDM Complications Study. Diabet Med 1998; 15 (05) 418-426 http://www.ncbi.nlm.nih.gov/pubmed/9609365
- 150 Seaquist ER, Goetz FC, Rich S et al. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989; 320 (18) 1161-1165 http://www.ncbi.nlm.nih.gov/pubmed/2710189
- 151 Sinclair SH, Malamut R, Delvecchio C et al. Diabetic retinopathy: treating systemic conditions aggressively can save sight. Cleve Clin J Med 2005; 72 (05) 447-454 http://www.ncbi.nlm.nih.gov/pubmed/15929458
- 152 Chaturvedi N, Stephenson JM, Fuller JH. The relationship between smoking and microvascular complications in the EURODIAB IDDM Complications Study. Diabetes Care 1995; 18 (06) 785-792 http://www.ncbi.nlm.nih.gov/pubmed/7555504
- 153 Laakso M. Epidemiology of diabetic dyslipidaemia. Diabetes Rev 1995; 3: 40-42
- 154 Taskinen MR, Smith U. Lipid disorders in NIDDM: implications for treatment. J Intern Med 1998; 244 (05) 361-370 http://www.ncbi.nlm.nih.gov/pubmed/9845851
- 155 Stern MP, Haffner SM. Dyslipidemia in type II diabetes. Implications for therapeutic intervention. Diabetes Care 1991; 14 (12) 1144-1159 http://www.ncbi.nlm.nih.gov/pubmed/1773701
- 156 Lahdenpera S, Syvanne M, Kahri J et al. Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: importance of serum triglycerides. Diabetologia 1996; 39 (04) 453-461 http://www.ncbi.nlm.nih.gov/pubmed/8777995
- 157 Tschöpe D, Rösen P. Gerinnungsstörungen bei metabolischem Syndrom und Typ 2 Diabetes. In: Mehnert H, editor. Herz, Gefäße und Diabetes. München: Medicon Verl; 1997: 117-132
- 158 Janka HU. Thrombozytenfunktion bei diabetischer Angiopathie. Stuttgart: Thieme; 1983
- 159 Gries FA, Peterson Braun M, Tschöpe D et al. Haemostasis and diabetic angiopathy. Stuttgart: Thieme; 1993
- 160 Colwell JA. Vascular thrombosis in type II diabetes mellitus. Diabetes 1993; 42 (01) 8-11 http://www.ncbi.nlm.nih.gov/pubmed/8420821
- 161 Chan P, Pan WH. Coagulation activation in type 2 diabetes mellitus: the higher coronary risk of female diabetic patients. Diabet Med 1995; 12 (06) 504-507 http://www.ncbi.nlm.nih.gov/pubmed/7648824
- 162 Carter AM, Grant PJ. Vascular homeostasis, adhesion molecules, and macrovascular disease in non-insulin-dependent diabetes mellitus. Diabet Med 1997; 14 (06) 423-432 http://www.ncbi.nlm.nih.gov/pubmed/9212306
- 163 American Diabetes Association (ADA). Aspirin therapy in diabetes. Diabetes Care 2000; 23 (Suppl. 01) S61-S62 http://www.ncbi.nlm.nih.gov/pubmed/12017681
- 164 Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364 (9435) 685-696 http://www.ncbi.nlm.nih.gov/pubmed/15325833
- 165 Gries FA, Bruns W, Grüneklee D. Therapieziele und Behandlungsstrategien beim Diabetes mellitus. Diabet Stoffw 2002; 11: 3-4
- 166 American Diabetes Association (ADA). Diagnosis and classification of diabetes mellitus. Diabetes Care 2004; 27 Suppl 1: S5-S10 http://www.ncbi.nlm.nih.gov/pubmed/14693921
- 167 European Diabetes Policy Group. A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group 1999. Diabet Med 1999; 16 (09) 716-730 http://www.ncbi.nlm.nih.gov/pubmed/10510947
- 168 Scherbaum WA, Lauterbach K, Joost HG. Deutsche Diabetes Gesellschaft (DDG) (eds.). Definition, Klassifikation und Diagnostik des Diabetes mellitus. Evidenzbasierte Diabetes-Leitlinien DDG. Düsseldorf: DDG; 2001
- 169 Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344 (18) 1343-1350 http://www.ncbi.nlm.nih.gov/pubmed/11333990
- 170 Kerner W, Brückel J. Definition, Klassifikation und Diagnostik des Diabetes mellitus. Diabet Stoffw 2010; 5 (Suppl. 02) S109-S112
- 171 Sacks DB, Arnold M, Bakris GL et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 2011; 34 (06) e61-e99 DOI: 10.2337/dc11-9998. http://www.ncbi.nlm.nih.gov/pubmed/21617108
- 172 Feskens EJ, Bowles CH, Kromhout D. Intra- and interindividual variability of glucose tolerance in an elderly population. J Clin Epidemiol 1991; 44 (09) 947-953 http://www.ncbi.nlm.nih.gov/pubmed/1890437
- 173 Mooy JM, Grootenhuis PA, de Vries H et al. Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia 1996; 39 (03) 298-305 http://www.ncbi.nlm.nih.gov/pubmed/8721775
- 174 Burke JP, Haffner SM, Gaskill SP et al. Reversion from type 2 diabetes to nondiabetic status. Influence of the 1997 American Diabetes Association criteria. Diabetes Care 1998; 21 (08) 1266-70 http://www.ncbi.nlm.nih.gov/pubmed/9702431
- 175 Ko GT, Chan JC, Woo J et al. The reproducibility and usefulness of the oral glucose tolerance test in screening for diabetes and other cardiovascular risk factors. Ann Clin Biochem 1998; 35 (01) 62-67 http://www.ncbi.nlm.nih.gov/pubmed/9463740
- 176 Schousboe K, Henriksen JE, Kyvik KO et al. Reproducibility of S-insulin and B-glucose responses in two identical oral glucose tolerance tests. Scand J Clin Lab Invest 2002; 62 (08) 623-630 http://www.ncbi.nlm.nih.gov/pubmed/12564620
- 177 Sievenpiper JL, Leiter LA, Vuksan V. Intrasubject coefficient of variation corresponds to diagnostic reproducibility in diabetes screening. Can J Diab 2002; 26: 105-112
- 178 de Vegt F, Dekker JM, Stehouwer CD et al. Similar 9-year mortality risks and reproducibility for the World Health Organization and American Diabetes Association glucose tolerance categories: the Hoorn Study. Diabetes Care 2000; 23 (01) 40-44 http://www.ncbi.nlm.nih.gov/pubmed/10857966
- 179 Kulzer B, Albus C, Herpertz S. Psychosoziales und Diabetes mellitus; DDG Praxis Leitlinie. Diabet Stoffw 2007; 2: S178-S183
- 180 Murphy R, Ellard S, Hattersley AT. Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab 2008; 4 (04) 200-213 http://www.ncbi.nlm.nih.gov/pubmed/18301398
- 181 Meissner T, Marquard J, Schober E. Maturity-onset diabetes of the young (MODY). Diabetologe 2010; 6 (03) 219-230 DOI: 10.1007/s11428-010-0543-5.
- 182 Keller H, Kramer L, Krones T et al. Evaluation der Implementierung von Innovationen am Beispiel von arriba® – eine Fokusgruppenstudie. Z Allg Med 2011; (01) 35-41
- 183 Sadowski EM, Eimer C, Keller H et al. Evaluation komplexer Interventionen: Implementierung von ARRIBA-Herz?. einer Beratungsstrategie für die Herz-Kreislaufprävention. ZFA 2005; 81 (10) 429-434
- 184 Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). JAMA 2001; 285 (19) 2486-2497 http://www.ncbi.nlm.nih.gov/pubmed/11368702
- 185 Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002; 105 (03) 310-315 http://www.ncbi.nlm.nih.gov/pubmed/11804985
- 186 Hippisley-Cox J, Coupland C, Vinogradova Y et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008; 336 (7659) 1475-1482 DOI: 10.1136/bmj.39609.449676.25. http://www.ncbi.nlm.nih.gov/pubmed/18573856
- 187 Keil U, Fitzgerald AP, Gohlke H et al. Risikoabschätzung tödlicher Herz-Kreislauf-Erkrankungen. Die neuen SCORE-Deutschland-Tabellen für die Primärprävention. Dtsch Arztebl 2005; 102 (25) A1808-A1812
- 188 Stevens RJ, Kothari V, Adler AI et al. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 2001; 101 (06) 671-679 http://www.ncbi.nlm.nih.gov/pubmed/11724655
- 189 Deutsches Institut für Ernährungsforschung Potsdam Rehbrücke (DIfE). Deutscher Diabetes-Risiko-Test® . 2007 [cited: 2013 Jul 04]. Available from: http://drs.dife.de/
- 190 Deutsche Diabetes-Stiftung (DDS). GesundheitsCheck Diabetes FINDRISK. 2007 [cited: 2013 Jul 04]. Available from: http://www.diabetes-risiko.de/risikotest.html
- 191 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Typ-2-Diabetes. Präventions- und Behandlungsstrategien für Fußkomplikationen. Langfassung. Mainz: Kirchheim; 2009 Available from: http://www.versorgungsleitlinien.de/themen/diabetes2/dm2_fuss/pdf/nvl_t2dfuss_lang.pdf
- 192 Whooley MA, Avins AL, Miranda J et al. Case-finding instruments for depression. Two questions are as good as many. J Gen Intern Med 1997; 12 (07) 439-445 http://www.ncbi.nlm.nih.gov/pubmed/9229283
- 193 World Health Organization (WHO). WHO (Fünf) – Fragebogen zum Wohlbefinden (Version 1998). 1998 [cited: 2013 Aug 12]. Available from: http://www.cure4you.dk/354/WHO-5_German.pdf
- 194 Turner RC, Cull CA, Frighi V et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281 (21) 2005-12 http://www.ncbi.nlm.nih.gov/pubmed/10359389
- 195 International Diabetes Federation (IDF). Self-Monitoring of Blood Glucose in Non-Insulin Treated Type 2 Diabetes. Guideline. 2009 [cited: 2013 Jul 04]. Available from: http://www.idf.org/webdata/docs/SMBG_EN2.pdf
- 196 Brown SA. Studies of educational interventions and outcomes in diabetic adults: a meta-analysis revisited. Patient Educ Couns 1990; 16 (03) 189-215 http://www.ncbi.nlm.nih.gov/pubmed/2149753
- 197 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Urin- und Blutzuckerselbstmessung bei Diabetes mellitus Typ 2. Abschlussbericht. Auftrag A05-08. Version 1.0. 2009 [cited: 2013 Apr 23]. Available from: http://www.iqwig.de/download/A05-08_Abschlussbericht_Zuckerselbstmessung_bei_Diabetes_mellitus_Typ_2.pdf
- 198 Clar C, Barnard K, Cummins E et al. Self-monitoring of blood glucose in type 2 diabetes: systematic review. Health Technol Assess 2010; 14 (12) 1-140 http://www.ncbi.nlm.nih.gov/pubmed/20226138
- 199 Müller N, Stengel D, Kloos C et al. Improvement of HbA1c and stable weight loss two years after an outpatient treatment and teaching programme for patients with type 2 diabetes without insulin therapy based on urine glucose self monitoring. Int J Gen Med 2012; (05) 241-247
- 200 Mann JI, De Leeuw I, Hermansen K et al. Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus. Nutr Metab Cardiovasc Dis 2004; 14 (06) 373-394 http://www.ncbi.nlm.nih.gov/pubmed/15853122
- 201 National Institute for Clinical Excellence (NICE). Type 2 Diabetes. National clinical guideline for management in primary and secondary care (update). London: Royal College Of Physicians; 2008 Available from: http://www.nice.org.uk/nicemedia/live/11983/40803/40803.pdf
- 202 Standards of medical care in diabetes – 2013. Diabetes Care 2013; 36 (Suppl. 01) S11-S66 DOI: 10.2337/dc13-S011. http://www.ncbi.nlm.nih.gov/pubmed/23264422
- 203 Pastors JG, Franz MJ, Warshaw H et al. How effective is medical nutrition therapy in diabetes care?. J Am Diet Assoc 2003; 103 (07) 827-831 http://www.ncbi.nlm.nih.gov/pubmed/12830019
- 204 Pastors JG, Warshaw H, Daly A et al. The evidence for the effectiveness of medical nutrition therapy in diabetes management. Diabetes Care 2002; 25 (03) 608-613 http://www.ncbi.nlm.nih.gov/pubmed/11874956
- 205 UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients, UKPDS Group. Metabolism 1990; 39 (09) 905-912 http://www.ncbi.nlm.nih.gov/pubmed/2392060
- 206 Franz MJ, Monk A, Barry B et al. Effectiveness of medical nutrition therapy provided by dietitians in the management of non-insulin-dependent diabetes mellitus: a randomized, controlled clinical trial. J Am Diet Assoc 1995; 95 (09) 1009-1017 http://www.ncbi.nlm.nih.gov/pubmed/7657902
- 207 Moore H, Summerbell C, Hooper L et al. Dietary advice for treatment of type 2 diabetes mellitus in adults. Cochrane Database Syst Rev 2004; (03) CD004097 http://www.ncbi.nlm.nih.gov/pubmed/15266517
- 208 Brown SA, Upchurch S, Anding R et al. Promoting weight loss in type II diabetes. Diabetes Care 1996; 19 (06) 613-624 http://www.ncbi.nlm.nih.gov/pubmed/8725861
- 209 Norris SL, Engelgau MM, Narayan KM. Effectiveness of self-management training in type 2 diabetes: a systematic review of randomized controlled trials. Diabetes Care 2001; 24 (03) 561-587 http://www.ncbi.nlm.nih.gov/pubmed/11289485
- 210 Dyson PA, Kelly T, Deakin T et al. Diabetes UK evidence-based nutrition guidelines for the prevention and management of diabetes. Diabet Med 2011; 28 (11) 1282-1288 http://www.ncbi.nlm.nih.gov/pubmed/21699560
- 211 de Souza RJ, Swain JF, Appel LJ et al. Alternatives for macronutrient intake and chronic disease: a comparison of the OmniHeart diets with popular diets and with dietary recommendations. Am J Clin Nutr 2008; 88 (01) 1-11 http://www.ncbi.nlm.nih.gov/pubmed/18614716
- 212 Sacks FM, Bray GA, Carey VJ et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009; 360 (09) 859-873 http://www.ncbi.nlm.nih.gov/pubmed/19246357
- 213 Toeller M, Müller-Wieland D. Keine speziellen diätetischen Lebensmittel mehr für Personen mit Diabetes mellitus. Diab Stoffw 2011; 6 (01) 29-31
- 214 Jenkins DJ, Wolever TM, Taylor RH et al. Glycemic index of foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr 1981; 34 (03) 362-366 http://www.ncbi.nlm.nih.gov/pubmed/6259925
- 215 Brand-Miller J, Hayne S, Petocz P et al. Low-glycemic index diets in the management of diabetes: a meta-analysis of randomized controlled trials. Diabetes Care 2003; 26 (08) 2261-2267 http://www.ncbi.nlm.nih.gov/pubmed/12882846
- 216 Anderson JW, Randles KM, Kendall CW et al. Carbohydrate and fiber recommendations for individuals with diabetes: a quantitative assessment and meta-analysis of the evidence. J Am Coll Nutr 2004; 23 (01) 5-17 http://www.ncbi.nlm.nih.gov/pubmed/14963049
- 217 Wolever TM, Gibbs AL, Mehling C et al. The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein. Am J Clin Nutr 2008; 87 (01) 114-125 http://www.ncbi.nlm.nih.gov/pubmed/18175744
- 218 Thomas DE, Elliott EJ. The use of low-glycaemic index diets in diabetes control. Br J Nutr 2010; 104 (06) 797-802 DOI: 10.1017/S0007114510001534. http://www.ncbi.nlm.nih.gov/pubmed/20420752
- 219 Hu FB, van Dam RM, Liu S. Diet and risk of Type II diabetes: the role of types of fat and carbohydrate. Diabetologia 2001; 44 (07) 805-817 http://www.ncbi.nlm.nih.gov/pubmed/11508264
- 220 Summers LK, Fielding BA, Bradshaw HA et al. Substituting dietary saturated fat with polyunsaturated fat changes abdominal fat distribution and improves insulin sensitivity. Diabetologia 2002; 45 (03) 369-377 http://www.ncbi.nlm.nih.gov/pubmed/11914742
- 221 Salmeron J, Hu FB, Manson JE et al. Dietary fat intake and risk of type 2 diabetes in women. Am J Clin Nutr 2001; 73 (06) 1019-1026 http://www.ncbi.nlm.nih.gov/pubmed/11382654
- 222 Kasiske BL, Lakatua JD, Ma JZ et al. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis 1998; 31 (06) 954-961 http://www.ncbi.nlm.nih.gov/pubmed/9631839
- 223 Pedrini MT, Levey AS, Lau J et al. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med 1996; 124 (07) 627-632 http://www.ncbi.nlm.nih.gov/pubmed/8607590
- 224 Robertson L, Waugh N, Robertson A. Protein restriction for diabetic renal disease. Cochrane Database Syst Rev 2007; (04) CD002181 http://www.ncbi.nlm.nih.gov/pubmed/17943769
- 225 Austin GL, Ogden LG, Hill JO. Trends in carbohydrate, fat, and protein intakes and association with energy intake in normal-weight, overweight, and obese individuals: 1971–2006. Am J Clin Nutr 2011; 93 (04) 836-843 http://www.ncbi.nlm.nih.gov/pubmed/21310830
- 226 Executive summary: Standards of medical care in diabetes-2012. Diabetes Care 2012; 35 (Suppl. 01) S4-S10 DOI: 10.2337/dc12-s004. http://www.ncbi.nlm.nih.gov/pubmed/22187471
- 227 Toeller M. Lifestyle Issues: Diet. In: Holt RIG, Cockram CS, Flyvbjerg A, Goldstein BJ, editors. Textbook of Diabetes. New York: Wiley; 2010: 346-357 DOI: 10.1002/9781444324808.ch22
- 228 Toeller M, Mann JI. Nutrition in the etiology and management of type 2 diabetes. In: Goldstein BJ, Müller-Wieland D, editors. Type 2 Diabetes. Principles and Practice. 2nd ed. New York: Informa Healthcare; 2008
- 229 Benack E, Gerlach S, Joost HG. Stellungnahme von diabetesDE und VDBD zu Stevia. 2012 [cited: 2013 Jun 26]. Available from: http://www.vdbd.de/Verband/Stellungnahme_diabetesDE_VDBD_Stevia_17-01-12.pdf
- 230 Greaves CJ, Sheppard KE, Abraham C et al. Systematic review of reviews of intervention components associated with increased effectiveness in dietary and physical activity interventions. BMC Public Health 2011; 11: 119 http://www.ncbi.nlm.nih.gov/pubmed/21333011
- 231 Paulweber B, Valensi P, Lindstrom J et al. A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res 2010; 42 (Suppl. 01) S3-S36 http://www.ncbi.nlm.nih.gov/pubmed/20391306
- 232 National Institutes of Health (NIH). Weight loss does not lower heart disease risk from type 2 diabetes. [press release] 2012 [cited: 2013 Jun 26]. Available from: http://www.nih.gov/news/health/oct2012/niddk-19.htm
- 233 Wadden TA, Neiberg RH, Wing RR et al. Four-Year Weight Losses in the Look AHEAD Study: Factors Associated With Long-Term Success. Obesity (Silver Spring) 2011; http://www.ncbi.nlm.nih.gov/pubmed/21779086
- 234 Wing RR, Lang W, Wadden TA et al. Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes. Diabetes Care 2011; 34 (07) 1481-1486 http://www.ncbi.nlm.nih.gov/pubmed/21593294
- 235 Belalcazar LM, Ballantyne CM, Lang W et al. Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study. Arterioscler Thromb Vasc Biol 2011; 31 (07) 1689-1695 http://www.ncbi.nlm.nih.gov/pubmed/21512162
- 236 Stewart TM, Bachand AR, Han H et al. Body image changes associated with participation in an intensive lifestyle weight loss intervention. Obesity (Silver Spring) 2011; 19 (06) 1290-1295 http://www.ncbi.nlm.nih.gov/pubmed/21151020
- 237 Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010; 170 (17) 1566-1575 http://www.ncbi.nlm.nih.gov/pubmed/20876408
- 238 Wing RR, Bolin P, Brancati FL et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369 (02) 145-154 DOI: 10.1056/NEJMoa1212914. http://www.ncbi.nlm.nih.gov/pubmed/23796131
- 239 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Steigerung der körperlichen Aktivität bei Diabetes mellitus Typ 2. Rapid Report A05-06A. Version 1.0. 2011 [cited: 2013 Jun 26]. Available from: https://www.iqwig.de/download/A05-06A_Kurzfassung_RR_Steigerung_der_koerperlichen_Aktivitaet_bei_Diabetes_mellitus_Typ_2.pdf
- 240 Colberg SR, Sigal RJ, Fernhall B et al. Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement. Diabetes Care 2010; 33 (12) e147-e167 DOI: 10.2337/dc10-9990. http://www.ncbi.nlm.nih.gov/pubmed/21115758
- 241 Boule NG, Haddad E, Kenny GP et al. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA 2001; 286 (10) 1218-1227 http://www.ncbi.nlm.nih.gov/pubmed/11559268
- 242 Boule NG, Kenny GP, Haddad E et al. Meta-analysis of the effect of structured exercise training on cardiorespiratory fitness in Type 2 diabetes mellitus. Diabetologia 2003; 46 (08) 1071-1081 http://www.ncbi.nlm.nih.gov/pubmed/12856082
- 243 Snowling NJ, Hopkins WG. Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta-analysis. Diabetes Care 2006; 29 (11) 2518-2527 http://www.ncbi.nlm.nih.gov/pubmed/17065697
- 244 Nielsen PJ, Hafdahl AR, Conn VS et al. Meta-analysis of the effect of exercise interventions on fitness outcomes among adults with type 1 and type 2 diabetes. Diabetes Res Clin Pract 2006; 74 (02) 111-120 http://www.ncbi.nlm.nih.gov/pubmed/16735074
- 245 Boule NG, Weisnagel SJ, Lakka TA et al. Effects of exercise training on glucose homeostasis: the HERITAGE Family Study. Diabetes Care 2005; 28 (01) 108-114 http://www.ncbi.nlm.nih.gov/pubmed/15616242
- 246 King DS, Baldus PJ, Sharp RL et al. Time course for exercise-induced alterations in insulin action and glucose tolerance in middle-aged people. J Appl Physiol 1995; 78 (01) 17-22 http://www.ncbi.nlm.nih.gov/pubmed/7713807
- 247 Physical Activity Guidelines Advisory Committee. Physical Activity Guidelines Advisory Committee Report. Washington, DC: U. S. Department of Health and Human Services; 2008 Available from: http://www.health.gov/paguidelines/report/pdf/CommitteeReport.pdf
- 248 Castaneda C, Layne JE, Munoz-Orians L et al. A randomized controlled trial of resistance exercise training to improve glycemic control in older adults with type 2 diabetes. Diabetes Care 2002; 25 (12) 2335-2341 http://www.ncbi.nlm.nih.gov/pubmed/12453982
- 249 Dunstan DW, Daly RM, Owen N et al. High-intensity resistance training improves glycemic control in older patients with type 2 diabetes. Diabetes Care 2002; 25 (10) 1729-1736 http://www.ncbi.nlm.nih.gov/pubmed/12351469
- 250 Sigal RJ, Kenny GP, Boule NG et al. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. Ann Intern Med 2007; 147 (06) 357-369 http://www.ncbi.nlm.nih.gov/pubmed/17876019
- 251 Cohen ND, Dunstan DW, Robinson C et al. Improved endothelial function following a 14-month resistance exercise training program in adults with type 2 diabetes. Diabetes Res Clin Pract 2008; 79 (03) 405-411 http://www.ncbi.nlm.nih.gov/pubmed/18006170
- 252 Ibanez J, Gorostiaga EM, Alonso AM et al. Lower muscle strength gains in older men with type 2 diabetes after resistance training. J Diabetes Complications 2008; 22 (02) 112-118 http://www.ncbi.nlm.nih.gov/pubmed/18280441
- 253 Ishii T, Yamakita T, Sato T et al. Resistance training improves insulin sensitivity in NIDDM subjects without altering maximal oxygen uptake. Diabetes Care 1998; 21 (08) 1353-1355 http://www.ncbi.nlm.nih.gov/pubmed/9702447
- 254 Strasser B, Siebert U, Schobersberger W. Resistance training in the treatment of the metabolic syndrome: a systematic review and meta-analysis of the effect of resistance training on metabolic clustering in patients with abnormal glucose metabolism. Sports Med 2010; 40 (05) 397-415 http://www.ncbi.nlm.nih.gov/pubmed/20433212
- 255 König D, Deibert P, Dickhut HH et al. Krafttraining bei Diabetes mellitus Typ 2. Dtsch Z Sportmed 2011; 62: 5-9
- 256 Cuff DJ, Meneilly GS, Martin A et al. Effective exercise modality to reduce insulin resistance in women with type 2 diabetes. Diabetes Care 2003; 26 (11) 2977-2982 http://www.ncbi.nlm.nih.gov/pubmed/14578226
- 257 Marcus RL, Smith S, Morrell G et al. Comparison of combined aerobic and high-force eccentric resistance exercise with aerobic exercise only for people with type 2 diabetes mellitus. Physical Therapy 2008; 88 (11) 1345-1354 http://www.ncbi.nlm.nih.gov/pubmed/18801851
- 258 Church TS, Blair SN, Cocreham S et al. Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: a randomized controlled trial. JAMA 2010; 304 (20) 2253-2262 http://www.ncbi.nlm.nih.gov/pubmed/21098771
- 259 Nelson ME, Rejeski WJ, Blair SN et al. Physical activity and public health in older adults: recommendation from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc 2007; 39 (08) 1435-1445 http://www.ncbi.nlm.nih.gov/pubmed/17762378
- 260 Hollmann W, Strüder HK, Tagarakis CV. Körperliche Aktivität, Gehirngesundheit und -leistungsfähigkeit. Nervenheilkunde 2003; 22 (09) 467-474
- 261 Marwick TH, Hordern MD, Miller T et al. Exercise training for type 2 diabetes mellitus: impact on cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009; 119 (25) 3244-3262 http://www.ncbi.nlm.nih.gov/pubmed/19506108
- 262 Desai MY, Nasir K, Rumberger JA et al. Relation of degree of physical activity to coronary artery calcium score in asymptomatic individuals with multiple metabolic risk factors. Am J Cardiol 2004; 94 (06) 729-732 http://www.ncbi.nlm.nih.gov/pubmed/15374775
- 263 Wackers FJ, Young LH, Inzucchi SE et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care 2004; 27 (08) 1954-1961 http://www.ncbi.nlm.nih.gov/pubmed/15277423
- 264 Balducci S, Zanuso S, Nicolucci A et al. Effect of an intensive exercise intervention strategy on modifiable cardiovascular risk factors in subjects with type 2 diabetes mellitus: a randomized controlled trial: the Italian Diabetes and Exercise Study (IDES). Arch Intern Med 2010; 170 (20) 1794-1803 http://www.ncbi.nlm.nih.gov/pubmed/21059972
- 265 Bernbaum M, Albert SG, Cohen JD et al. Cardiovascular conditioning in individuals with diabetic retinopathy. Diabetes Care 1989; 12 (10) 740-742 http://www.ncbi.nlm.nih.gov/pubmed/2612306
- 266 Albert SG, Bernbaum M. Exercise for patients with diabetic retinopathy. Diabetes Care 1995; 18 (01) 130-132 http://www.ncbi.nlm.nih.gov/pubmed/7698034
- 267 Aiello LP, Wong J, Cavallerano J et al. Retinopathy. In: Ruderman N, Devlin JT, Kriska A, (eds.) Handbook of Exercise in Diabetes. 2nd ed. Alexandria: ADA; 2002: 401-413
- 268 Willi C, Bodenmann P, Ghali WA et al. Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2007; 298 (22) 2654-2664 http://www.ncbi.nlm.nih.gov/pubmed/18073361
- 269 Willett WC, Green A, Stampfer MJ et al. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med 1987; 317 (21) 1303-1309 http://www.ncbi.nlm.nih.gov/pubmed/3683458
- 270 Hjermann I, Velve BK, Holme I et al. Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men. Lancet 1981; 2 (8259) 1303-1310 http://www.ncbi.nlm.nih.gov/pubmed/6118715
- 271 Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev 2004; (01) CD003041 http://www.ncbi.nlm.nih.gov/pubmed/14974003 DOI: 10.1002/14651858.CD003041.pub2.
- 272 Hermanson B, Omenn GS, Kronmal RA et al. Beneficial six-year outcome of smoking cessation in older men and women with coronary artery disease. Results from the CASS registry. . N Engl J Med 1988; 319 (21) 1365-1369 http://www.ncbi.nlm.nih.gov/pubmed/3185646
- 273 Doll R, Peto R, Boreham J et al. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004; 328 (7455) 1519 http://www.ncbi.nlm.nih.gov/pubmed/15213107
- 274 Lancaster T, Stead L. Physician advice for smoking cessation. Cochrane Database Syst Rev 2004; (04) CD000165 http://www.ncbi.nlm.nih.gov/pubmed/15494989
- 275 Fichtenberg CM, Glantz SA. Effect of smoke-free workplaces on smoking behaviour: systematic review. BMJ 2002; 325 (7357) 188 http://www.ncbi.nlm.nih.gov/pubmed/12142305
- 276 Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. JAMA 1982; 248 (12) 1465-1477 http://www.ncbi.nlm.nih.gov/pubmed/7050440
- 277 Peto R, Darby S, Deo H et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000; 321 (7257) 323-329 http://www.ncbi.nlm.nih.gov/pubmed/10926586
- 278 Singh S, Loke YK, Spangler JG et al. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011; 183 (12) 1359-1366 http://www.ncbi.nlm.nih.gov/pubmed/21727225
- 279 Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin (DGP). Tabakentwöhnung bei COPD. Pneumologie 2008; 62: 255-272
- 280 Fiore MC, Jaén CR, Baker TB. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville: U. S. Department of Health and Human Services. Public Health Service; 2008
- 281 UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 1991; 34 (12) 877-890 http://www.ncbi.nlm.nih.gov/pubmed/1778353